Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial Cystitis
Status:
Withdrawn
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the amount of improvement in bladder function and
pain relief with the administration of 2% alkalinized lidocaine in patients with interstitial
cystitis. Specifically, we want to see if the administration of 2% alkalinized lidocaine
treatments in the bladder improves urodynamic test result values. We hope to enroll
approximately 40 patients in this study.
Previous research has shown that the administration of 2% alkalinized lidocaine in the
bladder may improve the bladder's capacity to hold urine and urine flow rates while
simultaneously providing pain relief. As part of standard of care at the Smith Institute of
Urology Pelvic Pain Center, we routinely offer our IC patients 2% alkalinized lidocaine with
follow up urodynamic evaluation. Our research looks to expand upon the prior studies and
confirm the findings of improved bladder function and enhanced pain control of 2% alkalinized
lidocaine versus placebo by performing a second urodynamic evaluation, which is not routinely
performed.